Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement

Foster, C. S., Dodson, A. R., Ambroisine, L., Fisher, G., Møller, H., Clark, J., Attard, G., De-Bono, J., Scardino, P., Reuter, V. E., Cooper, C. S. ORCID: https://orcid.org/0000-0003-2013-8042, Berney, D. M. and Cuzick, J. (2009) Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement. British Journal of Cancer, 101 (7). pp. 1137-1144. ISSN 0007-0920

Full text not available from this repository. (Request a copy)

Abstract

* Background: This study was performed to test the hypothesis that expression of small heat shock protein Hsp-27 is, at diagnosis, a reliable predictive biomarker of clinically aggressive prostate cancer. * Methods: A panel of tissue microarrays constructed from a well-characterised cohort of 553 men with conservatively managed prostate cancer was stained immunohistochemically to detect Hsp-27 protein. Hsp-27 expression was compared with a series of pathological and clinical parameters, including outcome. * Results: Hsp-27 staining was indicative of higher Gleason score (P<0.001). In tissue cores having a Gleason score >7, the presence of Hsp-27 retained its power to independently predict poor clinical outcome (P<0.002). Higher levels of Hsp-27 staining were almost entirely restricted to cancers lacking ERG rearrangements (χ2 trend=31.4, P<0.001), although this distribution did not have prognostic significance. * Interpretation: This study has confirmed that, in prostate cancers managed conservatively over a period of more than 15 years, expression of Hsp-27 is an accurate and independent predictive biomarker of aggressive disease with poor clinical outcome (P<0.001). These findings suggest that apoptotic and cell-migration pathways modulated by Hsp-27 may contain targets susceptible to the development of biologically appropriate chemotherapeutic agents that are likely to prove effective in treating aggressive prostate cancers.

Item Type: Article
Additional Information: Funding Information: This work was funded by Cancer Research UK, National Cancer Research Institute, a specialised program of Research Excellence grant from the US National Cancer Institute, Grand Charity of Freemasons, Rosetrees Trust, The Bob Champion Cancer Trust, The Orchid Appeal, David Koch Foundation and North West Cancer Research Fund. Funding bodies had no involvement in the design and conduct of the study; in collection management, analysis and interpretation of the data; or in preparation, review and approval of the paper. We thank Jill Gosney for her assistance in preparing this paper.
Uncontrolled Keywords: heat shock protein 27,prognostic biomarker,prostate cancer,oncology,cancer research,sdg 3 - good health and well-being ,/dk/atira/pure/subjectarea/asjc/2700/2730
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 18 Jul 2022 12:30
Last Modified: 25 Jul 2022 00:24
URI: https://ueaeprints.uea.ac.uk/id/eprint/86456
DOI: 10.1038/sj.bjc.6605227

Actions (login required)

View Item View Item